/Regeneron%20Pharmaceuticals%2C%20Inc_%20pharmaceuticals%20by-%20okskaz%20via%20iStock.jpg)
Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $81.6 billion by market cap, the company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Evkeeza, Libtayo, Inmazeb, Arcalyst, and Zaltrap. The biotechnology company is expected to announce its fiscal fourth-quarter earnings for 2025 before the market opens on Friday, Jan. 30.
Ahead of the event, analysts expect REGN to report a profit of $8.06 per share on a diluted basis, down 18.6% from $9.90 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion.